TMS for First Responders in Washington State

Bipolar disorder has two sides - the highs (mania) and the lows (depression). For most people, the lows are where they spend most of their time, and the lows are usually what does the most damage to work, relationships, and day-to-day life. They're also the harder side to treat. Most bipolar medications are aimed at the highs, and many people try one after another for years without finding something that holds. TMS - a treatment that uses gentle magnetic pulses to the brain - is giving some of these patients a real option. But bipolar depression is trickier than regular depression, so we want to be straight with you about what TMS can and can't do, what the research actually shows, and how treatment works if you decide to try it. Is TMS approved for bipolar depression? Not yet. Right now, TMS is officially approved by the FDA for regular (non-bipolar) depression, for OCD, and for teens aged 15 and up with regular depression. For bipolar depression, doctors use it "off-label" - meaning it's allowed and widely used, but it doesn't yet carry a formal FDA approval for that specific condition. There has been a big step forward, though. In 2020, the FDA gave the NeuroStar TMS device - the one we use at Creative Wellness - something called a Breakthrough Device Designation for bipolar depression. That's the FDA saying, in effect: "This looks promising enough that we want to help it move through the approval pipeline faster." It's not full approval yet. But it's nothing either. Does it actually work? There's growing evidence that TMS can ease symptoms of bipolar depression - enough that the FDA granted NeuroStar (the device we use) Breakthrough Device Designation in 2020 to formally evaluate it for this use. Results vary from person to person. Some people respond well, some don't. We don't promise outcomes. What we can say confidently is that TMS is well-tolerated and safe for people with bipolar depression, without the systemic side effects that come with most bipolar medications.  One important note: there's some evidence that TMS can occasionally trigger a manic episode in a small number of bipolar patients. It's rare, but real - which is why we monitor closely throughout treatment. Before starting, an accurate diagnosis matters. Some patients have been labelled bipolar when the diagnosis isn't entirely clear, and a careful review sometimes identifies regular (unipolar) depression as the better fit, which changes the treatment plan and what insurance will cover.

For most patients, the insurance approval process for TMS is a black box. You submit information, wait, and eventually hear yes or no - often without a clear understanding of what happened in between or why the decision went the way it did. That lack of visibility is a problem because what happens behind the scenes matters. A well-prepared prior authorization submission significantly improves the likelihood of approval. A poorly documented one - or one that misses a specific insurer’s criteria - can result in a denial that takes weeks to appeal, delaying treatment the patient genuinely needs. Why TMS Requires Prior Authorization TMS is an FDA-approved treatment, but FDA approval and insurance coverage are entirely separate things. Insurers make their own coverage determinations based on their own clinical policies, which vary by provider and are updated periodically as the evidence base evolves. Most major insurers in Washington now cover TMS for treatment-resistant major depressive disorder, but they require prior authorization - a formal request from the treating clinic that demonstrates the patient meets their specific eligibility criteria before treatment begins. This is standard for any high-cost or specialist treatment, not unique to TMS. The keyword is “before.” Starting treatment without authorization in place is a significant financial risk. If coverage is denied after treatment has begun, the patient may be liable for the full cost. A clinic that allows this to happen is not doing its job. What Insurers Typically Require Each insurer has its own coverage policy, but most share a common set of core requirements. Understanding these in advance helps you arrive at your evaluation with the right history documented. Diagnosis T MS is covered fo r major depressive dis order (MDD) and, with some insurers, OCD . The diagnosis must be formally documented by a qualified clinician. Off-label uses - anxiety, PTSD, and others - are generally not covered, though this varies and is worth checking with your specific insurer. Prior medication trials Most insurers require documented evidence that the patient has tried and failed to respond to a minimum number of antidepressants - typically two to four, from different drug classes, at adequate doses and durations. “Failed to respond” means either no meaningful improvement or side effects that made the medication intolerable. This documentation needs to be specific: drug names, doses, duration, and outcome. Symptom severity Insurers typically require evidence of moderate to severe depression, usually demonstrated through a validated rating scale score. This is part of why the clinical evaluation matters - it generates the baseline data that supports the authorization request. Prior psychotherapy Some insurers also require documented evidence of prior psychotherapy, typically a course of CBT or equivalent. This requirement is not universal, but it appears in enough coverage policies that it is worth checking early. Medical necessity statement The treating clinician must provide a written statement explaining why TMS is medically necessary for this specific patient, given their history and current presentation. Vague or generic statements are a common reason for denials. The documentation needs to tell a clear, specific clinical story.

TMS is often described as a standalone treatment - and it can be. But the research, and clinical experience, point consistently in the same direction: patients who combine TMS with evidence-based therapy tend to do better. Not marginally better. Meaningfully better, with stronger outcomes and longer-lasting results. This article explains why that is, how CBT and ERP specifically complement what TMS does neurologically, and how care coordination works in practice when you’re receiving both treatments - whether from Creative Wellness directly or from an external therapy provider. Why TMS and Therapy Target Different Things TMS works by delivering magnetic pulses to specific areas of the brain involved in mood regulation. For depression, the primary target is the left dorsolateral prefrontal cortex - a region that is typically underactive in people with major depressive disorder. Repeated stimulation over a course of treatment helps restore more normal activity patterns in these neural circuits. What TMS does not do is change how you think. It does not teach coping skills, restructure unhelpful thought patterns, or help you process experiences that may be contributing to your symptoms. That is what therapy does. This is not a limitation of TMS - it is simply a different mechanism. The two approaches address different dimensions of the same condition. TMS creates the neurological conditions for improvement; therapy builds the cognitive and behavioural skills to sustain it. Used together, each makes the other more effective. What Is CBT and Why Does It Pair Well With TMS? Cognitive Behavioural Therapy (CBT) is one of the most extensively researched psychological treatments available. It is based on the principle that thoughts, feelings, and behaviours are interconnected - and that changing unhelpful thought patterns can directly improve mood and reduce symptoms. In practice, CBT helps patients identify automatic negative thoughts (such as catastrophising, black-and-white thinking, or self-blame), examine their accuracy, and replace them with more balanced, realistic perspectives. It also addresses behavioural patterns - particularly avoidance and withdrawal - that tend to maintain and deepen depression. The pairing with TMS is logical. TMS can lift the neurological floor - reducing the severity of depressive symptoms enough for a patient to engage meaningfully in therapy. Many patients find that CBT feels impossible when they are at their lowest; the cognitive effort required is simply too great. TMS can change that. As brain activity normalises, the capacity to engage with and benefit from therapy increases. Conversely, the insights and skills developed in CBT help protect the gains made through TMS. Depression tends to recur, and one of the strongest predictors of relapse is the absence of coping skills when symptoms begin to return . CBT directly addresses this vulnerability.

Finding the right antidepressant is, for many people, a frustrating process of trial and error. You try a medication, wait four to six weeks to assess whether it’s working, adjust the dose, manage side effects, and if it doesn’t work, start again with something else. For patients with treatment-resistant depression, this cycle can stretch across years. Pharmacogenetic testing - genetic testing applied to medication selection - is one of the more meaningful advances in psychiatric care precisely because it addresses this problem directly. At Creative Wellness TMS, we offer genetic testing as part of our integrated approach to treatment planning. This article explains what it is, how it works, and when it’s most useful alongside TMS and medication management. What Is Pharmacogenetic Testing? Pharmacogenetics is the study of how your genes affect your response to drugs. The same medication at the same dose can produce very different outcomes in different people - some respond well, some experience significant side effects , and some metabolize the drug so quickly or slowly that it never reaches a therapeutic level in the body. These differences are largely genetic. Variations in specific genes - particularly those governing liver enzymes responsible for drug metabolism - determine how your body processes psychiatric medications. By analyzing these genes, clinicians can make more informed decisions about which medications are likely to work for you, which are likely to cause problems, and at what dose. At Creative Wellness, the test examines 18 genes relevant to psychiatric medication response. It is completed across two appointments: a sample is collected at the first session, and results are reviewed with your clinician approximately two weeks later. Learn More: Genetic Testing Explained: Why We Offer It & What It Changes What the Results Actually Tell Your Clinician Genetic test results are typically presented in categories that reflect how your body is likely to process specific medications: Poor metabolizers process a drug more slowly than average, meaning standard doses can accumulate to levels that cause side effects. Rapid or ultrarapid metabolizers clear the drug too quickly for it to reach effective concentrations, which can explain why a medication appears not to work even at standard doses. Normal metabolizers fall within the expected range, meaning standard prescribing guidelines apply. This information is applied across the main classes of psychiatric medication - SSRIs, SNRIs, tricyclics, antipsychotics, mood stabilizers, and others. It tells your clinician which drugs from each class are likely to be well-tolerated and effective, which to approach with caution, and which to avoid. It is worth being clear about what the test does not do: it does not predict with certainty that a specific medication will work. Genetics is one factor among several - diagnosis, symptom profile, lifestyle, and other medications all play a role. But it substantially narrows the field and gives prescribing decisions a more solid foundation than symptom history alone.

If you’re considering TMS therapy, one of the first questions you probably have is: “Will I actually qualify?” The answer depends on a structured clinical evaluation - a process that goes well beyond a simple checklist. At Creative Wellness TMS, our clinicians assess multiple dimensions of your health history and current symptoms before recommending TMS. This article walks you through exactly what that evaluation involves, so you arrive at your first consultation fully informed. Why the Evaluation Matters TMS is not a one-size-fits-all treatment. It is FDA-approved for specific conditions, requires a meaningful time commitment (typically five sessions per week for four to six weeks) , and carries contraindications for certain patients. The evaluation exists to protect you - ensuring TMS is both safe and likely to be effective given your individual situation. Skipping or rushing this process would be a disservice. A thorough evaluation is what separates a treatment plan built around your needs from a generic one . Step 1: Confirming Your Diagnosis and Condition Severity The evaluation begins with a clear picture of your diagnosis. TMS is FDA-approved for: Treatment-resistant major depressive disorder (MDD) in adults Obsessive-compulsive disorder (OCD) Major depressive disorder in adolescents aged 15 and over (via the NeuroStar system, which Creative Wellness uses - the only FDA-cleared TMS device for this age group) TMS can also be offered as an off-label treatment for conditions including anxiety, PTSD, and certain neurological presentations . In these cases, your clinician will discuss the current evidence base with you and set realistic expectations around outcomes and insurance coverage. Symptom severity is assessed using standardized clinical tools. For depression, this typically involves validated rating scales that measure how significantly your symptoms are affecting your daily life - your sleep, concentration, mood, energy, and ability to function at work or in relationships. This baseline measurement also serves as a reference point for tracking your progress once treatment begins.

Transcranial magnetic stimulation (TMS) is a proven, FDA-approved treatment for conditions like treatment-resistant depression and OCD - and for many patients, a single course of TMS delivers meaningful, lasting relief. But for others, the journey looks a little different. Some patients benefit from a second course of TMS, periodic booster sessions, or an ongoing maintenance plan to sustain their results over time. If you've completed TMS and are wondering what comes next - or if your clinician has mentioned the possibility of additional treatment - this guide will help you understand why repeat courses happen, how decisions about further treatment are made, and what maintenance TMS can look like in practice. What Is a TMS Course, and How Does It Typically Work? A standard course of TMS at Creative Wellness typically involves daily sessions, five days a week, over four to six weeks. Each session lasts approximately 20 minutes. During treatment, magnetic pulses are precisely delivered to areas of the brain associated with mood regulation, gradually encouraging healthier neural activity. Many patients begin noticing improvements within the first few weeks, and results often continue to develop after the course concludes. For a significant proportion of patients, this initial course produces sustained symptom relief - sometimes for a year or more. However, TMS is not a one-size-fits-all treatment. The brain is complex, mental health conditions vary enormously between individuals, and factors like the severity of symptoms, prior treatment history, and the presence of other conditions all influence how someone responds to TMS. Why Some Patients Benefit From More Than One Course The need for additional TMS treatment doesn't mean the first course failed - in most cases, it means the opposite. Here are the most common reasons a patient might return for further TMS: 1. Symptom Recurrence Over Time C onditions like treatment-resistant depression are chronic for many people . Even when TMS produces an excellent initial response, symptoms can return over time - particularly during periods of heightened stress, major life changes, or seasonal shifts. This is not unique to TMS; it reflects the nature of the underlying condition. In these cases, a repeat course of TMS can effectively re-establish the neural changes that reduced symptoms in the first place. Research suggests that patients who have responded well to TMS previously are likely to respond well again. 2. Partial Response to the Initial Course Some patients experience meaningful improvement during their first TMS course but don't achieve full remission. This partial response is still clinically significant - and it often means the brain is showing signs of neuroplasticity that a second course can build upon. In these situations, a clinician may recommend adjusting the treatment protocol — including targeting different brain regions, modifying the frequency or intensity of pulses, or extending the overall course length — to optimize outcomes. 3. Complex or Comorbid Conditions Patients managing multiple mental health conditions - such as depression alongside PTSD, OCD, or anxiety - often have more complex treatment needs. TMS may need to be applied across different brain regions or protocols to address overlapping symptoms, which can mean a longer or more phased treatment journey. 4. Medication Changes or Life Stressors Significant changes to a medication regimen, a major health event, or a sustained period of stress can sometimes destabilize progress. TMS can play a stabilizing role during these periods, either through a short booster series or a more structured maintenance plan.

Quick overview When you begin Transcranial Magnetic Stimulation (TMS), one of the most important steps is motor-threshold mapping. Mapping is a quick, clinician-led procedure that measures how your brain responds to single magnetic pulses and uses that information to set a safe, personalized stimulation dose. Because TMS effectiveness and safety depend on correct dosing and placement, mapping is a cornerstone of MD-led TMS care at Creative Wellness. What is motor-threshold mapping? Motor-threshold mapping determines the smallest amount of magnetic energy needed to reliably produce a measurable motor response in a target muscle (usually a thumb or finger). That value - the motor threshold - tells clinicians how excitable the motor cortex is for a specific patient. The clinic then prescribes treatment intensity as a percentage of that threshold, so the therapeutic pulses are individualized rather than “one size fits all.” In practice, mapping is a physiologic test: the clinician delivers single TMS pulses over the motor cortex and observes or records the resulting muscle twitch or electrical signal. The result is an objective number that guides dosing and placement across the rest of the treatment. Mapping is both a safety and efficacy tool. What clinicians measure Motor response - the clinician looks for a consistent muscle twitch (typically in the hand/thumb) in response to single magnetic pulses. Some clinics use surface electromyography (EMG) to record muscle responses; others observe the twitch visually. Resting motor threshold (RMT) - the lowest stimulation intensity that produces a motor response a defined percentage of the time (a reproducible, clinic-defined threshold). RMT is the standard measure used to normalize the dose. Scalp coordinates - mapping also helps identify the motor cortex location relative to the patient’s scalp so clinicians can localize the treatment target ( for depression, typically the left dorsolateral prefrontal cortex ) with greater precision. How mapping determines treatment intensity Mapping converts a physiologic measurement (the motor threshold) into a personalized treatment dose. Treatment protocols are expressed as a percentage of the motor threshold - for example, a protocol may prescribe stimulation at a set percentage above RMT. By tying the dose to each patient’s threshold, clinicians ensure the brain receives effective, but not excessive, stimulation. Two practical benefits of this approach: Safety : By using an individualized threshold, clinicians reduce the chance of overstimulation, which helps minimize rare adverse events (for example, seizures) and other side effects. Effectiveness : Personalized dose improves the likelihood that the targeted brain region receives an adequate stimulation dose to produce meaningful changes in neural networks. Proper placement and dose together improve clinical outcomes over scalp-based “fixed” dosing methods.

Quick overview Your first Transcranial Magnetic Stimulation (TMS) consultation sets the clinical plan and expectations . Use this checklist to make the most of your visit - safety screening, medications, insurance, likely outcomes, and scheduling are all covered. Quick, how to use these lists Bring this checklist to your appointment (or print it). Ask the clinician any questions you don’t understand - you should leave the consult with a clear plan, a timeline, and next steps (benefit checks, mapping, prior-auths). Diagnosis & treatment goals Ask these to confirm why TMS is being recommended and what success looks like. “What is my (or my child’s) official diagnosis and why do you recommend TMS?” - Confirms medical rationale and whether TMS is first-line or for treatment-resistant cases. “What are realistic treatment goals for me?” - Ask about measurable goals (sleep, mood, school/work performance). “How will we measure success?” - Symptom scales, patient-reported changes, or clinical interviews. Safety & medical screening Safety is essential. These questions clarify screening steps and rare risks. “What screening do you do before TMS?” The clinic should describe seizure history review, neurologic checks, and device/implant screening. “Do I have any contraindications (implants, neurological issues, pregnancy)?” “What are the most common side effects, and how often do serious events (like seizures) occur?” Expect an honest but reassuring answer; the clinic should explain mitigation steps. “Who will be watching for side effects during sessions?” MD oversight and session checks should be explained. Medication & medical coordination Medications matter for safety and effectiveness - get specifics. “Which of my medications raises concern for TMS?” Ask about bupropion, high-dose TCAs, certain antipsychotics, stimulants, or benzodiazepines. The team should review your full med list and explain any needed coordination. “Do I need to stop or change any medicine before or during TMS?” Clinics usually won’t change meds without coordination; ask how they will work with your prescriber. “How will you coordinate with my psychiatrist or primary prescriber?” Expect a description of direct communication and shared decision-making. The MD evaluation, mapping & the treatment course Understand the clinical mechanics, so you know what to expect. “What happens at the MD evaluation and motor-threshold mapping?” Mapping personalizes dose and placement and is part of safety planning. Ask how long it takes and what it feels like. “How many sessions will I likely need, and what is a typical schedule?” Get a range (e.g., daily weekday sessions for ~4–6 weeks for many protocols) and whether plans are individualized. “What should I expect during a session?” Typical sensations, session length, and recovery (most return to normal activities). Insurance, prior authorization & cost Make sure administrative steps are clear. “Is TMS typically covered by my insurance? What documentation do you submit? Clinics should describe prior-auth requirements (diagnosis, med/therapy history) and benefits checks. (If TriWest or other military coverage applies, ask about adolescent specifics.) “How long does prior authorization usually take, and who will handle it?” Expect the clinic to manage submissions and follow-up. “What are likely out-of-pocket costs and payment options if we choose self-pay?” Learn More : Pricing

Quick overview Many teens 15 and older can be considered for Transcranial Magnetic Stimulation (TMS) , but eligibility depends on diagnosis, prior treatments, and insurance rules. This guide walks you through the clinical criteria, what TriWest’s change means for families, the paperwork you’ll need, and how Creative Wellness helps get teens from consult to treatment. The big change - TriWest and adolescent TMS In October 2025, TriWest updated its coverage policy to expand TMS coverage to adolescents ages 15 and older . That matters for military families and TriWest-covered dependents because it opens a pathway for in-network coverage of TMS for qualifying teens. NeuroStar also notes that NeuroStar Advanced Therapy is indicated as an adjunctive treatment for Major Depressive Disorder (MDD) in adolescents 15–21 . Clinical eligibility - the checklist clinicians (and insurers) look for Insurance policies and clinical teams generally use similar rules when deciding whether a teen is a candidate for TMS. Use this as a quick checklist : Basic clinical criteria Age: ≥ 15 years old (TriWest-adopted floor; NeuroStar adolescent indication 15–21). Primary diagnosis: Major Depressive Disorder (MDD) - documented by a psychiatrist or qualified clinician. Treatment history: Documented failure of at least two adequate antidepressant trials from different pharmacologic classes (for example, an SSRI + an SNRI), given at therapeutic dose and for an adequate duration. Insurers require clear dates, doses, and reasons for discontinuation. Psychotherapy tried: The teen has not responded adequately to psychotherapy (e.g., CBT) - usually documented therapist notes or a clinician summary are required. Safety / absolute contraindications (typically reviewed during clinical screening) Presence of non-MRI-compatible metal in the head (implants) that would make TMS unsafe. Certain neurological conditions (e.g., uncontrolled seizure disorder) - TMS is generally safe, but seizure history requires physician review. Other medical factors identified during the MD evaluation (cardiac devices, implanted stimulators, etc.). See your clinic’s safety checklist. (Your clinic will screen thoroughly.) Some insurers require an explicit statement that TMS is being requested as a medical treatment for MDD after medication and therapy failures, not as an elective procedure. What documentation to gather - a parent’s checklist When you contact Creative Wellness (or another clinic) and when the clinic files an insurance prior authorization, having clear documentation speeds decisions. Collect the following before the consult whenever possible: A. Psychiatric documentation Recent psychiatric evaluation (or summary) stating diagnosis of MDD and current symptoms. Medication history : names of antidepressants, start/stop dates, doses, duration, and reasons for discontinuation or perceived inadequacy (side effects, lack of benefit). Insurers expect explicit documentation that at least two antidepressants from different classes were tried adequately. Lab / medical notes if applicable (e.g., relevant medical history that affects treatment). B. Psychotherapy documentation Therapist progress notes or summary showing that an evidence-based psychotherapy (e.g., CBT) was tried and did not provide an adequate response. Dates and frequency of therapy are helpful. C. School / functional impact (helpful but optional) A short letter about how symptoms are affecting school, social life, or daily functioning can strengthen medical necessity arguments. D. Insurance & ID Front/back of insurance card, subscriber info, and any military/membership ID (e.g., TriWest details). For TriWest patients, note the adolescent coverage update (Oct 21, 2025) and be prepared to request eligibility confirmation. E. Contact information for prior providers Therapist and prescriber contact details so the clinic can obtain records when needed.